Catalog No.
RHC21704
Species reactivity
Human, Monkey
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
IF: 1:200-1:1000, IHC: 1:200-1:1000, WB: 1:500-1:2000
Target
NPM, Nucleolar protein NO38, Numatrin, NPM1, Nucleolar phosphoprotein B23, Nucleophosmin
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P06748
Applications
IF, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R2Z97
A High-Throughput, Flow Cytometry Approach to Measure Phase Behavior and Exchange in Biomolecular Condensates., PMID:40502052
Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein., PMID:40269321
Screening colorectal cancer associated autoantigens through multi-omics analysis and diagnostic performance evaluation of corresponding autoantibodies., PMID:40240912
IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia., PMID:40229904
Generation of a Rat Monoclonal Antibody for Human Nucleophosmin., PMID:39976521
Aerosol immunization with influenza matrix, nucleoprotein, or both prevents lung disease in pig., PMID:39397062
The roles of phosphorylation of signaling proteins in the prognosis of acute myeloid leukemia., PMID:39035053
High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia., PMID:38963637
Inhibition of nucleophosmin/B23 sensitizes ovarian cancer cells to immune check-point blockade via PD-L1 in ovarian cancer., PMID:38821736
Extramedullary infiltration in pediatric acute myeloid leukemia: Results from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative., PMID:38644612
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations., PMID:38215358
How I treat refractory and relapsed acute myeloid leukemia., PMID:37944143
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial., PMID:37187198
Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?, PMID:37187197
Identification and evaluation of novel serum autoantibody biomarkers for early diagnosis of gastric cancer and precancerous lesion., PMID:37079049
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting., PMID:36869366
Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients., PMID:36795117
The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands., PMID:36555547
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML., PMID:36383712
Frequency of Nucleophosmin 1 Expression by Immunohistochemistry in Acute Myeloid Leukemia., PMID:36258732
A clinicopathological experience in acute myeloid leukemia: Effects of clinical data and status of FLT3, CEBPA and NPM1 on prognosis., PMID:35900493
Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody., PMID:35799423
Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors., PMID:35682627
Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges., PMID:35551633
Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia., PMID:35216478
Potentiation of Recombinant NP and M1-Induced Cellular Immune Responses and Protection by Physical Radiofrequency Adjuvant., PMID:34960128
Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia., PMID:34903734
Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed Pigs., PMID:34804053
A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML)., PMID:34573408
Discovering Panel of Autoantibodies for Early Detection of Lung Cancer Based on Focused Protein Array., PMID:33968062
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial., PMID:33765335
Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia., PMID:33564120
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial., PMID:33367545
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses., PMID:33356418
Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells., PMID:33281829
Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer., PMID:33185955
How I diagnose and treat NPM1-mutated AML., PMID:33171486
CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia., PMID:33046866
Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia., PMID:32923866
Nucleophosmin, a multifunctional nucleolar organizer with a role in DNA repair., PMID:32853771
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment., PMID:32781546
Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic., PMID:32609881
Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment., PMID:32051557
Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study., PMID:31851556
Flow cytometric identification and cell-line establishment of macrophages in naked mole-rats., PMID:31784606
NPM and NPM-MLF1 interact with chromatin remodeling complexes and influence their recruitment to specific genes., PMID:31675375
Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells., PMID:31616059
Nucleolin and nucleophosmin expression in seminomas and non-seminomatous testicular tumors., PMID:31513277
Using recursive partitioning approach to select tumor-associated antigens in immunodiagnosis of gastric adenocarcinoma., PMID:30950146
Early treatment of acute promyelocytic leukaemia is accurately guided by the PML protein localisation pattern: real-life experience from a tertiary New Zealand centre., PMID:30876657
For research use only. Not for human or drug use.
